載入中
NASDAQHealthcareBiotechnology
最新資料
US$0.89
−US$0.0549 · -5.81%
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
前收盤價
US$0.89
−US$0.0549 · -5.81%
盤中時間採用ET。市場資料可能有所延遲。
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
日內區間
目前US$0.89
52週區間
目前US$0.89
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
42
合理估值
情緒
51
多空交錯
風險
69
高風險
動能
37
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
日內區間
目前US$0.89
52週區間
目前US$0.89
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（SGD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 31.92萬 SGD | 6.95萬 SGD | 50.91萬 SGD | 36.56萬 SGD | — |
| 銷貨成本 | 120.58萬 SGD | 1.71萬 SGD | 3736 SGD | 10.9萬 SGD | 3501 SGD |
| 毛利 | −88.66萬 SGD | 5.24萬 SGD | 50.54萬 SGD | −10.9萬 SGD | 11.03萬 SGD |
| 研究與開發 | 218.21萬 SGD | 190.95萬 SGD | 159.4萬 SGD | 152.22萬 SGD | 109.02萬 SGD |
| 銷售、一般及管理費用 | 144.18萬 SGD | 126.57萬 SGD | 49.05萬 SGD | 59.65萬 SGD | 58.85萬 SGD |
| 營業費用 | 363.32萬 SGD | 318.29萬 SGD | 208.45萬 SGD | 217.42萬 SGD | 126.69萬 SGD |
| 利息收入 | 12.19萬 SGD | 31.77萬 SGD | 28.15萬 SGD | 2046 SGD | 3389 SGD |
| 利息支出 | 2.06萬 SGD | 2.03萬 SGD | 5.05萬 SGD | 12.21萬 SGD | 11.84萬 SGD |
| 折舊和攤銷 | 40.16萬 SGD | 33.54萬 SGD | 38.11萬 SGD | 39.29萬 SGD | 32.99萬 SGD |
| 營業利益 | −451.98萬 SGD | −313.05萬 SGD | −157.92萬 SGD | −228.32萬 SGD | −115.63萬 SGD |
| 淨利 | −391.68萬 SGD | −251.67萬 SGD | −414.42萬 SGD | −305.55萬 SGD | −207.37萬 SGD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
